Researchers from the Institut Pasteur-Paris found that gene variations that influence susceptibility to dengue fever and dengue shock syndrome differ among world populations, according to a study in the journal PLOS Neglected Tropical Diseases. "The particular genetic risk conferred by these genes indicates that Southeast and Northeast Asians are highly susceptible to both phenotypes, while Africans are best protected against DSS and Europeans best protected against DF, but the most susceptible to DSS," the study team wrote.
Diphenyleneiodonium selectively inhibited cancer stem cells' ability to produce essential vitamins, starving the cells and rendering them dormant and thus more vulnerable to conventional treatment, researchers reported in Aging. The drug did not produce toxic side effects, the researchers said.
Bioverativ awarded a $100 million contract to the UK's Oxford BioMedica to develop lentiviral vectors for use in Bioverativ's hemophilia gene therapies. Oxford BioMedica will receive an upfront payment of $5 million and will be eligible for several milestone payments, with a potential value exceeding $100 million, as well as royalties on sales of Bioverativ's hemophilia therapies that are under development.
Agios Pharmaceuticals' new-drug application for ivosidenib, which is being developed as a treatment for patients with isocitrate dehydrogenase 1 mutation-positive relapsed/refractory acute myeloid leukemia, was accepted for priority review by the FDA. The PDUFA date for the drug is Aug. 21.
Topics creating a buzz this week in the AABB HUB include intraoperative blood recovery, the appropriate dose of Rh immune globulin, ISBT labels for pooled apheresis plasma and blood collection bags. To sign up for email alerts for new posts or responses, click the envelope icon on the left tab of the group. Select one of the threads below to follow the discussion or submit a comment.